García-Romero, NPalacín-Aliana, IMadurga, RCarrión-Navarro, JEsteban-Rubio, SusanaJiménez, BCollazo, APérez-Rodríguez, FOrtiz de Mendivil, AFernández-Carballal, CGarcía-Duque, SDiamantopoulos-Fernández, JBelda-Iniesta, CristobalPrat-Acín, RCalvo, EAyuso-Sacido, AngelSánchez-Gómez, Pilar2020-09-072020-09-072020-06-22BMC Med . 2020 Jun 22;18(1):142.1741-7015http://hdl.handle.net/20.500.12105/10986Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment. We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo. We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance. Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment.engVoRhttp://creativecommons.org/licenses/by/4.0/AngiogenesisBevacizumabGlioblastomaNeovasculogenesisVEGFAAtribución 4.0 Internacional3256477418114210.1186/s12916-020-01610-01741-7015BMC medicineopen access